Progression-free survival of daratumumab vs bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: TAURUS chart review study Meeting Abstract
| Authors: | Gordan, L.; Tan, C. R.; Vescio, R.; Ye, J. C.; Schinke, C.; Medhekar, R.; Fu, A. Z.; Lafeuille, M. H.; Thompson-Leduc, P.; Khare, V.; Reitan, J.; Milkovich, G.; Kaila, S.; Davies, F.; Usmani, S. Z. |
| Abstract Title: | Progression-free survival of daratumumab vs bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: TAURUS chart review study |
| Meeting Title: | 11th Annual Meeting of the Society of Hematologic Oncology (SOHO 2023): Progress in Personalized Therapy |
| Keywords: | progression-free survival; mm; real-world; multicenter chart review; transplant ineligible newly diagnosed multiple myeloma |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 23 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Sep 6-9 |
| Meeting Location: | Houston, TX |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S502 |
| Language: | English |
| ACCESSION: | WOS:001062479600588 |
| PROVIDER: | wos |
| DOI: | 10.1016/S2152-2650(23)01457-X |
| Notes: | Meeting Abstract: MM-493 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
